Götz Gerecke
Managing Director & Senior Partner
Zurich
Götz Gerecke joined Boston Consulting Group in 1995 in London and is a core member of the firm’s Health Care practice. He heads BCG's medtech commercial business worldwide and is the leader for medtech and the Marketing,Sales & Pricing practice in Switzerland. He is also responsible for BCG's recruiting in Central Europe, the Middle East, and Africa.
Götz has worked intensively with clients in the medtech, biopharma, consumer goods, retail, travel and tourism, and private equity industries. His passion is for generating growth, and much of his recent work has focused on go-to-market strategy and commercial model transformation. He is an expert in commercial excellence, business model innovation, organization, lean management, driving large-scale change, and private equity.
From 1998 to 2005, Götz left BCG to become cofounder and managing partner of Wellness Business Partners, an advisory and private equity firm dedicated to the European health and wellness industries. He was also a principal with private equity fund Compass Partners International.
Before joining BCG, Götz worked in investment banking for Morgan Stanley and as a finance manager for Procter & Gamble.
Götz is a qualified corporate-finance representative for the Securities and Futures Authority in London.
Hospitals are increasingly buying medtech products and services less on the basis of initial purchase price and more on the total value they create—for patients, clinical staff, and society.
Some medtech CEOs have embraced value-based health care and the business opportunity it represents, but many remain cautious. That’s understandable—but strategically misguided. Companies don’t have the luxury to wait.
BCG’s second global benchmarking study finds that the industry has made limited progress in fixing its commercial model. Yet firms that take action are posting strong shareholder returns.
The health care industry is in the midst of sweeping changes. Given high investor expectations and pressure on prices and profit margins, medtech companies must take action.
